{
    "organizations": [],
    "uuid": "4d84ed407e3c7edf26218be72027793c839f947d",
    "author": "",
    "url": "https://www.reuters.com/article/brief-aerie-pharmaceuticals-announces-us/brief-aerie-pharmaceuticals-announces-u-s-launch-of-rhopressa-0-02-idUSFWN1S70P0",
    "ord_in_thread": 0,
    "title": "BRIEF-Aerie Pharmaceuticals Announces U.S. Launch Of Rhopressa 0.02%",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30, 2018 / 10:45 AM / in 13 minutes BRIEF-Aerie Pharmaceuticals Announces U.S. Launch Of Rhopressa 0.02% Reuters Staff\nApril 30 (Reuters) - Aerie Pharmaceuticals Inc:\n* AERIE PHARMACEUTICALS ANNOUNCES U.S. LAUNCH OF RHOPRESSAÂ® (NETARSUDIL OPHTHALMIC SOLUTION) 0.02%\n* AERIE - FORMULARY CONTRACTS FOR COMMERCIAL INSURANCE COVERAGE IN 2018, MEDICARE PART D PROGRAM COVERAGE BEGINNING 2019 IN FINAL STAGES OF EXECUTION Source text for Eikon: Further company coverage:",
    "published": "2018-04-30T13:45:00.000+03:00",
    "crawled": "2018-04-30T14:07:22.178+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "minute",
        "pharmaceutical",
        "announces",
        "launch",
        "rhopressa",
        "reuters",
        "staff",
        "april",
        "reuters",
        "aerie",
        "pharmaceutical",
        "inc",
        "aerie",
        "pharmaceutical",
        "announces",
        "launch",
        "netarsudil",
        "ophthalmic",
        "solution",
        "aerie",
        "formulary",
        "contract",
        "commercial",
        "insurance",
        "coverage",
        "medicare",
        "part",
        "program",
        "coverage",
        "beginning",
        "final",
        "stage",
        "execution",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}